Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genasense in Waldenstrom's Macroglobulinemia
NCT00062244Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2003
- Primary completion
- Jun 2007
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of oblimersen in Waldenstrom macroglobulinemia (WM), sponsored by National Cancer Institute. Started May 2003; status: completed.
02
Drugs
oblimersen
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00062244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062244.